Last 202.50 GBp
Change Today 0.00 / 0.00%
Volume 0.0
SLN On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 7:35 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
202.50 GBp
Previous Close
202.50 GBp
Day High
202.50 GBp
Day Low
202.50 GBp
52 Week High
02/25/14 - 388.75 GBp
52 Week Low
10/16/14 - 168.00 GBp
Market Cap
105.5M
Average Volume 10 Days
47.1K
EPS TTM
-0.23 GBp
Shares Outstanding
52.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a biotechnology company, discovers, develops, and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases primarily in North America and the Asia/Pacific. It has AtuRNAi, an RNAi platform, which encompasses the generation of potent chemically stabilized siRNA molecules. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and DBTC delivery system, which delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma. Its products include Atu027, which is in a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as in a Phase Ib clinical trial for head and neck cancer; Atu111 that is in pre-clinical stage for the treatment of lung diseases; and Atu112, which is in the pre-clinical stage for the treatment of systemic disorders. The company is also developing products for immunotherapy. Silence Therapeutics plc has partnership and collaboration agreements with various pharmaceutical companies, including Pfizer/Quark Pharmaceuticals, Novartis, AstraZeneca, Dainippon Sumitomo Pharma Co., Ltd., InteRNA Technologies B.V., Mirna Therapeutics Inc., and miRagen Therapeutics, Inc. The company is based in London, the United Kingdom.

38 Employees
Last Reported Date: 06/4/14

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 70.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 119.0K GBP
Chief Operating Officer
Total Annual Compensation: 58.0K GBP
Chief Medical Officer and Director
Total Annual Compensation: 53.0K GBP
Compensation as of Fiscal Year 2013.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Appoints Lars Karlsson as Head of Research and Development from January 05, 2015

Silence Therapeutics plc has appointed Dr. Lars Karlsson as Head of Research and Development from January 05, 2015. He will also join the board as an executive director. He joins Silence from Novo Nordisk where he was the Vice President for Auto-Immune Disease Pharmacology. He was previously Head of Translational Immunology at Norvo Nordisk. Prior to this, Lars was also Vice President of Immunology and Fibrosis at micro RNA therapeutics company, Regulus Therapeutics.

Silence Therapeutics plc - Shareholder/Analyst Call

Silence Therapeutics plc - Shareholder/Analyst Call

Silence Therapeutics plc Announces Publication of First-In-Human Study Data on Use of Atu027 RNAi in Advanced Solid Tumours

Silence Therapeutics plc announced that study data on the first in human trial of the use of its Atu027 RNAi (RNA interference) technology in patients with advanced solid tumours has on November 18, 2014 been pre-published online by the Journal of Clinical Oncology, the peer reviewed journal and official publication of the American Society of Clinical Oncology (ASCO). The study found that Atu027 was well tolerated and safe in patients with advanced solid tumours.  Disease stabilisation was also achieved in 41% of patients for at least eight weeks after treatment. The final analysis of this study was also presented in a verbal update session at the ASCO Annual Meeting in June 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 202.50 GBp 0.00

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.92 AUD +0.035
Galena Biopharma Inc $1.53 USD +0.04
Marina Biotech Inc $0.67 USD +0.02
Prosensa Holding NV $18.82 USD +0.06
Tekmira Pharmaceuticals Corp C$16.42 CAD +0.22
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,080.7x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,151.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.